ClinicalTrials.gg
RecruitingNCT07308106Updated Jul 30, 2026

A Phase II Clinical Study of SKB571 as Monotherapy in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer With MET Abnormalities

A Phase 2 interventional study of SKB571 for injection in Non-small Lung Cancer, sponsored by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-07-30.

Sponsored by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (part of Sichuan Kelun Pharmaceutical Co.,Ltd.) · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Apr 2026; still recruiting 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
70
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 844 studies in Lung Neoplasms with a site in China — 371 open to participants now, 418 under way, 34 of them phase 3. Lung Neoplasms · China.

Planned enrollment
324th of 585
70 · median 90
Started
2026
with 88 others
Phase 2
151 of 844
73 open now
Primary completion
2027-06
later than 258 of 417 live
Registered
736th of 844
by date

Among the 844 studies in Lung Neoplasms with a site in China, this one is the 324th largest by planned enrollment of the 585 interventional ones that give a count, is one of 89 that started in 2026, is one of 151 in phase 2, reaches primary completion later than 258 of the 417 other live ones, and was the 736th registered.

Lung Neoplasms

5,424 studies on the registry are indexed under Lung Neoplasms; 1,345 are open to participants now.

Browse Lung Neoplasms studies →

Open to participants now

371 of the 844 studies in Lung Neoplasms with a site in China are open now. Recruiting first, the newest first:

366 more — sign in →

All 371 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 995 Lung Neoplasms studies recruiting now, 682 (69%) set no upper age limit and 142 (14%) stop at 75 or younger; 45 take children under 18; 142 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 844 studies in Lung Neoplasms with a site in China, or all of them as a file.
02

Study summary

The aim of the study to evaluate the safety and efficacy of SKB571 for injection as monotherapy in patients with locally advanced or metastatic Non-Small Cell Lung Cancer with MET abnormalities. Eligible subjects will receive SKB571 monotherapy, until radiographic disease progression, intolerable toxicity, discontinuation of study treatment required by the subject, or other protocol-specified treatment discontinuation criteria, whichever occurs first.

03

Conditions studied

  • Non-small Lung Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female, age ≥ 18 years and ≤ 75 years at the time of signing the form (ICF).
  2. Participants with or cytologically confirmed NSCLC.
  3. Locally advanced or NSCLC with MET Abnormalities that has progressed after standard therapy.
  4. At least one as assessed by the investigator according to v1.1.
  5. (ECOG) performance status of 0 or 1 within 7 days before the first dose.
  6. ≥ 3 months as assessed by the investigator.
  7. Adequate organ and bone marrow function.
  8. Male and female participants must agree to use highly effective methods of during the study treatment period.
  9. Participants must voluntarily join this study, sign the ICF, and be able to comply with the visits and related procedures specified in the protocol.

Exclusion criteria

Exclusion Criteria:

  1. Participants with known active central nervous system (CNS) , and/or carcinomatous meningitis, brainstem metastasis, metastases to spinal cord, or spinal cord compression.
  2. Participants with other malignant tumors within 3 years prior to the first dose.
  3. Presence of any of the following cardiovascular and cerebrovascular diseases or cardiovascular and cerebrovascular risk factors.
  4. Presence of severe and/or uncontrolled concomitant diseases.
  5. Participants with a history of interstitial lung disease (ILD) or a history of non-infectious pneumonitis.
  6. Clinically severe lung damage due to complications of lung disorder.
  7. Risk of esophagotracheal fistula or esophagopleural fistula, or tumor invasion or compression of surrounding vital organs and blood vessels.
  8. Toxicity from prior anti-tumor therapy has not recovered to ≤ Grade 1.
  9. Known active pulmonary tuberculosis.
  10. Known history of allogeneic organ transplant or hematopoietic stem cell transplant.
  11. Active and .
  12. Positive test for (HIV) or a medical history of acquired immunodeficiency syndrome (AIDS); known active syphilis infection.
  13. Known allergy or to SKB571 or its ; or a history of severe allergy to other monoclonal antibodies.
  14. Participants who have undergone major surgery within 4 weeks before the first dose or are expected to require major surgery during the study.
  15. Serious infection within 4 weeks before the first dose.
  16. Participants who have received systemic therapy with > 10 mg/day of prednisone or other drugs within 2 weeks before the first dose of study treatment.
  17. Participants who have received a within 30 days before the first dose, or plan to receive a live vaccine during the study.
  18. Pregnant or breastfeeding women.
  19. Have local or systemic diseases caused by non-malignant tumors, or diseases or symptoms secondary to tumors.
  20. Any condition that, in the investigator's opinion, interferes with the evaluation of study treatment, participant safety, or interpretation of study results, or any other condition that the investigator deems unsuitable for participation in this study.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
70 participants (estimated)

Study arms

  • Experimental
    SKB571 monotherapy

    Drug: SKB571 for injection

Interventions

06

What researchers measure

Primary outcomes

  1. AE

    Incidence and severity of adverse events (AEs)

    Time frame: Up to 24 months

  2. ORR

    Objective response rate (ORR) assessed by the investigator as per RECIST v1.1.

    Time frame: Up to 24 months

Secondary outcomes

  1. DCR

    Disease control rate (DCR) (assessed by the investigators as per RECIST v1.1)

    Time frame: Up to 24 months

  2. DOR

    Time from the start of the first assessment of CR or PR in tumor patients to PD or death due to any reason.

    Time frame: Up to 24 months

  3. PFS

    Time from start of treatment to progression of disease (PD) or death, whichever occurs first, in patients with tumors.

    Time frame: Up to 24 months

  4. OS

    Time from start of treatment to death due to any reason.

    Time frame: Up to 24 months

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for Jun 2027, 14 months after the start.

Of 77 industry-sponsored phase 2 interventional studies under Lung Neoplasms, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 61. This study's planned 14 months is below that.

Counting every sponsor, half of 364 studies reached it within 65 months; a quarter within 34 and three quarters within 105.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 15, 2025
First posted
Dec 29, 2025
StartActual
Apr 3, 2026
Primary completionEst.
Jun 30, 2027
CompletionEst.
Mar 31, 2029
Last update
Jul 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07308106
Responsible party
Sponsor
First posted
Dec 29, 2025
Start date
Apr 3, 2026
Primary completion
Jun 30, 2027 (estimated)
Completion
Mar 31, 2029 (estimated)
Last update
Jul 30, 2026

Study contacts

Yina Diao
Contact
diaoyina@kelun.com
028-67252634

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: SKB571

Start the discussion